ASH is hematology's home event: the largest annual US meeting focused on blood cancers and other hematologic disorders, with an exhibit hall that draws well over 275 companies across pharma, diagnostics, and research supply. Landing in mid-December, it also functions as a natural checkpoint for closing out hematology-account activity before the January reset around JPM Healthcare Week.
What ASH is
The American Society of Hematology Annual Meeting & Exposition covers hematology and hematologic malignancies specifically, a narrower and more specialized audience than a general oncology meeting like ASCO. It draws clinical and research hematologists, pharmaceutical sponsors with hematology-focused programs, and the CROs, CDMOs, and diagnostics vendors serving that pipeline. ASH has stated its exhibit hall regularly draws more than 275 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and non-profit organizations.
The GTM signal at ASH
Exhibiting at that scale of show reflects a real, budgeted decision to be visible in front of the hematology community specifically, which makes it a strong company-level signal for any account working on a blood-cancer or blood-disorder program. A named presenter on the agenda is the sharpest available hook: a specific person, a specific dataset, and a specific date. Attendance alone is the weakest of the three signals but still worth acting on for accounts that already clear your fit bar. For the full framework, see selling around life science conferences.
The outreach window
ASH registration for exhibitors and the broader public typically opens well ahead of the meeting, giving a multi-week window to cross-reference exhibitor and speaker information against your account list before the show. That pre-show window, once floor plans and speaking agendas are public, is the highest-leverage point to reach out with a specific, timely reason tied to the show. During the show, outreach still lands but competes with a packed clinical schedule; after ASH wraps, a reference to a specific session holds up for a few weeks before it starts reading as stale, particularly given how close ASH sits to the holiday and January-reset period.
Who this matters most for
A CRO running hematology or blood-cancer trials should treat ASH as a near-direct match for its buyer, on the same tier as ASCO for solid-tumor oncology. A CDMO with cell and gene therapy or biologics capability relevant to hematologic disease should watch which sponsors are exhibiting as a signal of advancing programs. A diagnostics or tools vendor serving hematology labs will find ASH one of the tightest-fit shows on the calendar for that specific buyer.